Neurogene Inc. Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer

Chartwell Partners proudly announces its collaboration with Neurogene Inc., a pioneering clinical-stage company dedicated to delivering groundbreaking genetic therapies for individuals and families grappling with rare neurological conditions on the recruitment of Julie Jordan, M.D., as their esteemed Chief Medical Officer.

With a wealth of experience spanning over two decades in both industry and clinical settings, Dr. Jordan brings invaluable expertise to Neurogene. Her extensive background encompasses the orchestration of global clinical trials across diverse therapeutic areas, including gene therapy and disorders of the central nervous system.

Prior to joining Neurogene, Dr. Jordan served as the Chief Medical Officer at Homology Medicines, where she spearheaded clinical development and operational initiatives. Her leadership was instrumental in driving regulatory interactions and supporting translational research endeavors, focusing on gene therapy and gene editing solutions for rare diseases. Dr. Jordan’s contributions were integral to the successful advancement of several pioneering genetic medicine programs during her tenure.

Before her role as Chief Medical Officer, Dr. Jordan held the position of Senior Vice President, Head of Clinical Development and Operations at Homology Medicines. Here, she demonstrated exceptional leadership skills by overseeing the development of innovative genetic therapies and addressing regulatory hurdles. Additionally, she played a pivotal role in fostering collaborations with patient advocacy groups and thought leaders, further enhancing the company’s mission.

Prior to her tenure at Homology Medicines, Dr. Jordan held significant leadership positions in global pharmaceutical companies such as Cerevel Therapeutics, Avanir Pharmaceuticals, and Teva Pharmaceutical Industries. Her responsibilities encompassed various therapeutic areas, including central nervous system disorders and neuropsychiatry, showcasing her versatile expertise.

Dr. Jordan’s journey into industry was preceded by a decade-long career as a practicing physician. She served as a Clinical Instructor of Medicine at Harvard Medical School and worked in the Department of Medicine at Massachusetts General Hospital (MGH). Dr. Jordan holds an A.B. in Biology from Harvard College and earned her M.D. from Harvard Medical School. She completed her residency in Internal Medicine at MGH, Harvard Medical School, further solidifying her foundation in clinical practice and research.

With Dr. Jordan’s exceptional leadership and extensive experience, Neurogene is poised to continue its mission of revolutionizing genetic medicine for rare neurological diseases, offering hope and transformative solutions to patients worldwide.